CV Sciences (CVSI) FCF Margin (2013 - 2026)

CV Sciences (CVSI) posted FCF Margin of 3.07% for Q1 2026, up 132.83% sequentially from 9.34% in Q4 2025, and up 642.0% YoY from 0.41% in Q1 2025.

CV Sciences (CVSI) FCF Margin (2013 - 2026) Analysis & Trends

CV Sciences has reported FCF Margin for 14 years, with the latest figure at 3.07% in Q1 2026.

Quarterly FCF Margin rose 642.0% year-over-year to 3.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.17% (up 98.0% YoY) and the FY2025 annual result came in at 3.69%, up 191.0% from the prior year.
FCF Margin improved to 3.07% in Q1 2026 per CVSI's latest filing, from 9.34% in the prior quarter.
Over five years, FCF Margin peaked at 35.58% in Q2 2023 and troughed at 28.25% in Q2 2022.
A 5-year average of 1.49% and a median of 3.16% in 2024 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2024: FCF Margin jumped 6383 bps in 2023, then plunged 3702 bps in 2024.
Over 5 years, FCF Margin stood at 5.43% in 2022, then tumbled by 155 bps to 3.0% in 2023, then tumbled by 56 bps to 4.69% in 2024, then slumped by 99 bps to 9.34% in 2025, then surged by 133 bps to 3.07% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 3.07%, 9.34%, and 9.74% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	7.41%
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	21.80%
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	14.87%
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	26.25%
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	8.76%
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	13.41%
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	17.84%
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	CV Sciences	4.10 Mn	3.84 Mn	1.45 Mn	0.44%

Download Data